Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

January 31, 2013

Conditions
TumorOvarian Cancer
Interventions
DRUG

NKTR-102 q14d

NKTR-102 given on a q14 day schedule

DRUG

NKTR-102 q21d

NKTR-102 given on a q21 day schedule

Trial Locations (20)

22908

Investigator Site - Charlottesville, Charlottesville

27103

Investigator Site - Winston-Salem, Winston-Salem

33401

Investigator Site - West Palm Beach, West Palm Beach

37203

Investigator Site - Nashville, Nashville

48912

Investigator Site - Lansing, Lansing

52242

Investigator Site - Iowa City, Iowa City

73142

Investigator Site - Oklahoma City, Oklahoma City

90033

Investigator Site - Los Angeles, Los Angeles

92346

Investigator Site - Higland, Highland

92663

Investigator Site - Newport Beach, Newport Beach

02915

Investigator Site - East Providence, East Providence

Unknown

Investigator Site - Gent, Ghent

Investigator Site - Leuven, Leuven

Investigator Site - Liege, Liège

Investigator Site - Wilrijk, Wilrijk

Investigator Site - Middlesex, Middlesex

Investigator Site - Coventry, Coventry

DD1 9SY

Investigator Site - Dundee, Dundee

G12 OYN

Investigator Site - Glasgow, Glasgow

NE7 7DN

Investigator Site - Newcastle Upon Tyne, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Nektar Therapeutics

INDUSTRY